{"filing":{"accession_number":"0001125345-26-000050","cik":"0001125345","ticker":"MGNX","company_name":"MACROGENICS INC","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"mgnx-20260723.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000050/mgnx-20260723.htm"},"events":[{"id":20042,"run_id":18044,"accession_number":"0001125345-26-000050","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"MacroGenics disclosed a clinical update on its Phase 1 study of MGC026, reporting that the SCCHN cohort met pre-specified response thresholds and is advancing to Stage 2 enrollment, with interim results accepted for presentation at ESMO Congress 2026. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, but does not fit the specific event types (earnings, M\u0026A, impairment, etc.); it represents progress in the company's core drug development pipeline and would affect investor assessment of the registrant's clinical prospects.","company_name":"MACROGENICS INC","ticker":"MGNX","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19299,"accession_number":"0001125345-26-000050","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MacroGenics disclosed a clinical update on its Phase 1 study of MGC026, reporting that the SCCHN cohort met pre-specified response thresholds and is advancing to Stage 2 enrollment, with interim results accepted for presentation at ESMO Congress 2026. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, but does not fit the specific event types (earnings, M\u0026A, impairment, etc.); it represents progress in the company's core drug development pipeline and would affect investor assessment of the registrant's clinical prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:12:17.056632+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19299,"accession_number":"0001125345-26-000050","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MacroGenics disclosed a clinical update on its Phase 1 study of MGC026, reporting that the SCCHN cohort met pre-specified response thresholds and is advancing to Stage 2 enrollment, with interim results accepted for presentation at ESMO Congress 2026. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, but does not fit the specific event types (earnings, M\u0026A, impairment, etc.); it represents progress in the company's core drug development pipeline and would affect investor assessment of the registrant's clinical prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:12:17.056632+00:00","company_name":"MACROGENICS INC","ticker":"MGNX","filing_date":"2026-07-23"}]}